Bristol-Myers Squibb (BMY) Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of OS with Opdivo Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated GBM
Go back to Bristol-Myers Squibb (BMY) Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of OS with Opdivo Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated GBM| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 48.30 +0.46 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.84 | 52 Week High | $77.12 | |||
| Open | $47.93 | 52 Week Low | $49.03 | |||
| Day High | $48.41 | P/E | 31.36 | |||
| Day Low | $47.62 | EPS | $1.54 | |||
| Volume | 10,917,320 | |||||
